HUS1700037I1 - A 8-[{1-(3,5-bisz-(trifluor-metil)-fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]dekan-2-on hidroklorid sója, és eljárás elõállítására - Google Patents

A 8-[{1-(3,5-bisz-(trifluor-metil)-fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]dekan-2-on hidroklorid sója, és eljárás elõállítására

Info

Publication number
HUS1700037I1
HUS1700037I1 HUS1700037C HUS1700037C HUS1700037I1 HU S1700037 I1 HUS1700037 I1 HU S1700037I1 HU S1700037 C HUS1700037 C HU S1700037C HU S1700037 C HUS1700037 C HU S1700037C HU S1700037 I1 HUS1700037 I1 HU S1700037I1
Authority
HU
Hungary
Prior art keywords
phenyl
decan
diaza
spiro
trifluoromethyl
Prior art date
Application number
HUS1700037C
Other languages
English (en)
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38542035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1700037(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of HUS1700037I1 publication Critical patent/HUS1700037I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUS1700037C 2006-04-05 2017-10-16 A 8-[{1-(3,5-bisz-(trifluor-metil)-fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]dekan-2-on hidroklorid sója, és eljárás elõállítására HUS1700037I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78928006P 2006-04-05 2006-04-05
EP07774640.2A EP2004646B1 (en) 2006-04-05 2007-04-04 Hydrochloride salt of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor

Publications (1)

Publication Number Publication Date
HUS1700037I1 true HUS1700037I1 (hu) 2017-11-28

Family

ID=38542035

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE07774640A HUE028908T2 (hu) 2006-04-05 2007-04-04 A 8-[{1-(3,5-bisz-(trifluor-metil)-fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]dekan-2-on hidroklorid sója, és eljárás elõállítására
HUS1700037C HUS1700037I1 (hu) 2006-04-05 2017-10-16 A 8-[{1-(3,5-bisz-(trifluor-metil)-fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]dekan-2-on hidroklorid sója, és eljárás elõállítására

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE07774640A HUE028908T2 (hu) 2006-04-05 2007-04-04 A 8-[{1-(3,5-bisz-(trifluor-metil)-fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]dekan-2-on hidroklorid sója, és eljárás elõállítására

Country Status (16)

Country Link
US (5) US8178550B2 (hu)
EP (4) EP2662374A1 (hu)
JP (3) JP5352446B2 (hu)
CN (2) CN102276606B (hu)
AR (1) AR060353A1 (hu)
CA (1) CA2648604C (hu)
ES (1) ES2584838T3 (hu)
HU (2) HUE028908T2 (hu)
LT (1) LTPA2017031I1 (hu)
MX (1) MX2008012935A (hu)
PE (3) PE20071220A1 (hu)
PL (1) PL2004646T3 (hu)
PT (1) PT2004646T (hu)
SG (2) SG170838A1 (hu)
TW (1) TWI363058B (hu)
WO (1) WO2007117486A2 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
SG10201500028RA (en) 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
PT2004646T (pt) * 2006-04-05 2016-07-14 Opko Health Inc Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
PL2346823T3 (pl) 2008-09-05 2016-01-29 Opko Health Inc Związki pośrednie w syntezie związków 8-[{1-(3,5-bis-(trifluorometylo)fenylo)etoksy}metylo]-8-fenylo-1,7-diaza-spiro[4.5]dekan-2-onu
JP5860399B2 (ja) * 2009-08-14 2016-02-16 オプコ ヘルス， インコーポレイテッド ニューロキニン−１アンタゴニストの静脈内用製剤
CN105017251B (zh) * 2015-06-30 2018-06-29 齐鲁制药有限公司 一种nk-1受体拮抗剂的制备方法及其中间体
FR3047665B1 (fr) 2016-02-17 2020-12-11 Pf Medicament Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法
AU2020317734A1 (en) * 2019-07-25 2022-02-17 Intervet International B.V. Crystalline form of telmapitant or (5R,8S)-8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,3,7-triazaspiro(4.5)decane-2,4-dione
EP4125875A1 (en) 2020-04-03 2023-02-08 NeRRe Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
BR112022024208A2 (pt) 2020-06-02 2022-12-20 Nerre Therapeutics Ltd Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678409B2 (en) 1992-10-28 1997-05-29 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
EP0673367A1 (en) 1992-12-14 1995-09-27 MERCK SHARP & DOHME LTD. 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
AU685212B2 (en) 1994-01-13 1998-01-15 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
WO1997007804A1 (en) 1995-08-28 1997-03-06 Schering Corporation Combination therapy for advanced cancer comprising temozolomide and cisplatin
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
HRP980370B1 (en) 1997-07-02 2002-10-31 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist
TR200400313T3 (tr) * 2001-02-12 2004-04-21 Teva Pharma Okskarbazepinin yeni kristal biçimleri ve bu biçimlerin hazirlanmasi için islemler
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
GB0321256D0 (en) * 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
AU2004308935A1 (en) * 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
US7498438B2 (en) 2004-04-07 2009-03-03 Schering Corporation Fused ring NK1 antagonists
SG187416A1 (en) * 2004-07-01 2013-02-28 Opko Health Inc Piperidine derivatives as nk1 antagonists
US20060100188A1 (en) 2004-11-09 2006-05-11 Chen Zong Treatment methods
PT2004646T (pt) * 2006-04-05 2016-07-14 Opko Health Inc Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação
SG10201500028RA (en) * 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
PE20080353A1 (es) 2006-04-05 2008-04-25 Schering Corp Sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona y proceso de preparacion de las mismas
RU2500679C2 (ru) * 2006-08-07 2013-12-10 Палау Фарма, С.А. Кристаллические противогрибковые соединения
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
PL2346823T3 (pl) 2008-09-05 2016-01-29 Opko Health Inc Związki pośrednie w syntezie związków 8-[{1-(3,5-bis-(trifluorometylo)fenylo)etoksy}metylo]-8-fenylo-1,7-diaza-spiro[4.5]dekan-2-onu
JP5860399B2 (ja) * 2009-08-14 2016-02-16 オプコ ヘルス， インコーポレイテッド ニューロキニン−１アンタゴニストの静脈内用製剤

Also Published As

Publication number Publication date
AR060353A1 (es) 2008-06-11
SG10201500027TA (en) 2015-02-27
LTPA2017031I1 (lt) 2017-11-10
EP2004646B1 (en) 2016-06-08
US20100048601A1 (en) 2010-02-25
US20070244142A1 (en) 2007-10-18
CN101437821A (zh) 2009-05-20
CA2648604A1 (en) 2007-10-18
EP2662374A1 (en) 2013-11-13
PE20071220A1 (es) 2007-12-14
EP2676957A1 (en) 2013-12-25
PT2004646T (pt) 2016-07-14
US20150210693A1 (en) 2015-07-30
CN101437821B (zh) 2014-06-04
JP5352446B2 (ja) 2013-11-27
WO2007117486A3 (en) 2008-02-14
US10196394B2 (en) 2019-02-05
PE20142329A1 (es) 2015-01-30
JP5856944B2 (ja) 2016-02-10
ES2584838T3 (es) 2016-09-29
JP6122411B2 (ja) 2017-04-26
PE20120545A1 (es) 2012-05-21
JP2009532472A (ja) 2009-09-10
SG170838A1 (en) 2011-05-30
WO2007117486A2 (en) 2007-10-18
JP2014240437A (ja) 2014-12-25
EP2662373A1 (en) 2013-11-13
CN102276606B (zh) 2013-06-12
US8178550B2 (en) 2012-05-15
CN102276606A (zh) 2011-12-14
MX2008012935A (es) 2008-10-15
TW200815439A (en) 2008-04-01
PL2004646T3 (pl) 2016-12-30
HUE028908T2 (hu) 2017-01-30
US20190375751A1 (en) 2019-12-12
EP2004646A2 (en) 2008-12-24
US20130281477A1 (en) 2013-10-24
US8470842B2 (en) 2013-06-25
JP2013032404A (ja) 2013-02-14
TWI363058B (en) 2012-05-01
CA2648604C (en) 2016-05-24

Similar Documents

Publication Publication Date Title
HUS1700037I1 (hu) A 8-[{1-(3,5-bisz-(trifluor-metil)-fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]dekan-2-on hidroklorid sója, és eljárás elõállítására
SG10201500028RA (en) Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
TWI350185B (en) Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one salts and tablets made therefrom
HRP20130536T1 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
IL205220A0 (en) 8 - [4 - (1 - AMINOCYCLOBUTYL)PHENYL]-9- PHENYL [1,2,4] TRIAZOLO [3,4-f]- 1,6 - NAPHTHYRIDINS AND THEIR USE FOR THE PREPARATION OF A MEDICAMENT FOR TREATING CANCER
PL1797288T3 (pl) Katalizowany filtr sadzy o zrównoważonym ciśnieniu
EP1843805A4 (en) ANTIMICROBIAL NEEDLE COATING FOR ADVANCED INFUSION
EP1983831A4 (en) PHENYL AND PYRIDIL COMPOUNDS FOR INFLAMMATION AND IMMUNOUS USE
HK1098700A1 (en) Use of drug combinations for treating insulin resistance
IL182464A0 (en) Compounds for nonsense suppression, and methods for their use
EP2120959A4 (en) METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA
HK1213738A1 (zh) 包含 -巰基吡啶- -氧化物和吡咯衍生物的殺生物組合物
SI2097381T1 (sl) 4-(4-((4-kloro-3-(trifluorometil)fenil))karbamoil)amino)-3- fluorofenoksi)-n-metilpiridin-2-karbokasamid monohidrat
EP2332927A4 (en) HETEROCYCLIC COMPOUND CONTAINING NITROGEN AND AGENT FOR CONTROLLING HARMFUL ANIMALS
EP2053021A4 (en) POROUS ORGANOSILICIUM ZEOLITE, ITS PREPARATION AND USE METHOD
IL177366A0 (en) Substituted azetidine compounds as cyclooxygease-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
IL197448A0 (en) Methods for administering long-lasting hypoglycemic agents
IL194770A0 (en) 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine and its use as a medicament
HK1158623A1 (en) Intermediates for the synthesis of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)- ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds 8-[1-(35--())--]-8--17-- [45]-2-
IL212179A0 (en) Nitrogenous heterocyclic compounds, preparation thereof, and use thereof as antibacterial agents
IL201252A0 (en) New nitrogenated heterocyclic compounds, their preparation and use as antibacterial drugs
EP2036909A4 (en) SPIROCYCLOPIPERAZINE QUATERNARY AMMONIUM SALT TYPE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
EP2016504A4 (en) CONSTRUCTION OF A SOCIAL ACTIVITY PROFILE OF A PARTICIPANT IN A COMMUNICATION NETWORK
GB0719592D0 (en) Compound, use and method
GB0819432D0 (en) Compound, composition and use